Monday was a big day for our chardonnay guzzling friends as Paul Hudson officially took the helm. Early reports have Mr. Hudson embarking on a fact-finding mission as he looks to transform Sanofi into a viable player again. While we can’t speak to other aspects of the Sanofi portfolio when it comes to diabetes Paul has his work cut out for him. Although the best possible move just might be to dump this franchise, we consider this an unlikely scenario.
Yet there is one part of diabetes that he just might undo, he could take advantage of the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.